5H-Dibenzo[a,d]cycloheptene-2,8-dicarboxamide, 5-[(2S)-2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]propyl]-10,11-dihydro-N,N,N',N'-tetramethyl-5-(1H-tetrazol-5-yl)-

• 分子结构分类: 有机化合物 - 苯类化合物 - 二苯并环庚烯
• 英文名称: 5H-Dibenzo[a,d]cycloheptene-2,8-dicarboxamide, 5-[(2S)-2-[[2-[(2S)-2-cyano-1-pyrrolidinyl]-2-oxoethyl]amino]propyl]-10,11-dihydro-N,N,N',N'-tetramethyl-5-(1H-tetrazol-5-yl)-
• 英文别名: 2-[2-[[2-(2-cyanopyrrolidin-1-yl)-2-oxoethyl]amino]propyl]-6-N,6-N,13-N,13-N-tetramethyl-2-(2H-tetrazol-5-yl)tricyclo[9.4.0.03,8]pentadeca-1(11),3(8),4,6,12,14-hexaene-6,13-dicarboxamide
• 化学式: C₃₂H₃₉N₉O₃
• 分子量: 597.7
• InChiKey: NVSWJKWHLUTHLP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  44
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  151
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• DIABETES THERAPY
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP3124041A1

  公开（公告）日：2017-02-01

  The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a DPP-4 inhibitor and a long-acting insulin. The invention further relates to a DPP-4 inhibitor for subcutaneous or transdermal use.

  本发明涉及治疗和/或预防代谢性疾病的方法，包括联合使用 DPP-4 抑制剂和长效胰岛素。本发明还涉及一种皮下或透皮使用的 DPP-4 抑制剂。
• TREATMENT FOR DIABETES IN PATIENTS WITH INSUFFICIENT GLYCEMIC CONTROL DESPITE THERAPY WITH AN ORAL OR NON-ORAL ANTIDIABETIC DRUG
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP3150204A2

  公开（公告）日：2017-04-05

  The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.

  本发明涉及的发现是，某些 DPP-4 抑制剂特别适用于治疗和/或预防代谢性疾病，特别是糖尿病，尤其是在使用口服和/或非口服抗糖尿病药物治疗后仍血糖控制不佳的患者中。
• TREATMENT FOR DIABETES IN PATIENTS INAPPROPRIATE FOR METFORMIN THERAPY
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP3598974A1

  公开（公告）日：2020-01-29

  The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients for whom metformin therapy is inappropriate due to intolerability or contraindication against metformin.

  本发明涉及的发现是，某些 DPP-4 抑制剂特别适用于治疗和/或预防因不能耐受二甲双胍或对二甲双胍有禁忌症而不适合使用二甲双胍治疗的患者的代谢性疾病，尤其是糖尿病。
• DPP-IV INHIBITORS FOR USE IN THE TREATMENT OF NAFLD
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2303262B1

  公开（公告）日：2018-01-17
• DPP-4 INHIBITORS FOR USE FOR THE TREATMENT OF WOUND HEALING IN DIABETIC PATIENTS
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2326326B1

  公开（公告）日：2019-10-09